Laboratory of Nutritional Biochemistry, National Institute of Gastroenterology, "S. de Bellis" Research Hospital, 70013 Castellana Grotte (BA), Italy.
Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology, "S. de Bellis" Research Hospital, 70013 Castellana Grotte (BA), Italy.
Int J Mol Sci. 2021 Mar 12;22(6):2880. doi: 10.3390/ijms22062880.
The administration of a ketogenic diet (KD) has been considered therapeutic in subjects with irritable bowel syndrome (IBS). This study aimed to investigate the molecular mechanisms by which a low-carbohydrate diet, such as KD, can improve gastrointestinal symptoms and functions in an animal model of IBS by evaluating possible changes in intestinal tissue expression of endocannabinoid receptors. In rats fed a KD, we detected a significant restoration of cell damage to the intestinal crypt base, a histological feature of IBS condition, and upregulation of CB1 and CB2 receptors. The diet also affected glucose metabolism and intestinal membrane permeability, with an overexpression of the glucose transporter GLUT1 and tight junction proteins in treated rats. The present data suggest that CB receptors represent one of the molecular pathways through which the KD works and support possible cannabinoid-mediated protection at the intestinal level in the IBS rats after dietary treatment.
生酮饮食(KD)的应用在肠易激综合征(IBS)患者中被认为具有治疗作用。本研究旨在通过评估肠道组织中内源性大麻素受体表达的可能变化,来研究低碳水化合物饮食(如 KD)如何在 IBS 动物模型中改善胃肠道症状和功能的分子机制。在接受 KD 喂养的大鼠中,我们检测到对肠道隐窝基底细胞损伤的显著恢复,这是 IBS 状态的一个组织学特征,同时还上调了 CB1 和 CB2 受体。该饮食还影响葡萄糖代谢和肠膜通透性,治疗组大鼠的葡萄糖转运蛋白 GLUT1 和紧密连接蛋白表达上调。这些数据表明,CB 受体是 KD 作用的分子途径之一,并支持在饮食治疗后,IBS 大鼠的肠道水平可能存在大麻素介导的保护作用。